Thrombosis
|
0.580 |
Biomarker
|
phenotype |
CTD_human |
Effect of sodium pentosan polysulphate on the thrombogenicity of prothrombin complex concentrates.
|
1279834 |
1992 |
Thrombosis
|
0.580 |
Biomarker
|
phenotype |
CTD_human |
Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
|
10064001 |
1999 |
Thrombosis
|
0.580 |
Biomarker
|
phenotype |
CTD_human |
Deep vein thrombosis during enoxaparin prophylactic treatment in a young pregnant woman homozygous for factor V Leiden and heterozygous for the G127-->a mutation in the thrombomodulin gene.
|
11132655 |
2000 |
Thrombosis
|
0.580 |
GeneticVariation
|
phenotype |
LHGDN |
A single-base change (G to A) at position 20210 in the 3' untranslated region of the prothrombin gene is associated with increased plasma levels of prothrombin and might therefore increase the risk for thrombosis.
|
12865818 |
2003 |
Thrombosis
|
0.580 |
GeneticVariation
|
phenotype |
LHGDN |
Group 1: A total of 377 children with thrombosis were analyzed during 7 years between January 1997 and 2004 and screened for prothrombin G20210A mutation.
|
16020118 |
2005 |
Thrombosis
|
0.580 |
GeneticVariation
|
phenotype |
LHGDN |
The G20210A prothrombin gene, factor V Leiden, and MTHFR C677T mutations have been identified as predisposing genetic factors for thrombosis.
|
15958894 |
2005 |
Thrombosis
|
0.580 |
GeneticVariation
|
phenotype |
LHGDN |
Prothrombin G20210A gene variant is not associated with idiopathic portal vein thrombosis in an area endemic for portal vein thrombosis.
|
16283309 |
2006 |
Thrombosis
|
0.580 |
Biomarker
|
phenotype |
LHGDN |
However, a prothrombin 20210 defect should be considered in the differential diagnosis of patients with unexplained thrombosis.
|
17342369 |
2007 |
Thrombosis
|
0.580 |
Biomarker
|
phenotype |
CTD_human |
Cerebral venous sinus thrombosis as a recurrent thrombotic event in a patient with heterozygous prothrombin G20210A genotype after discontinuation of oral anticoagulation therapy: how long should we treat these patients with warfarin?
|
17245631 |
2007 |
Thrombosis
|
0.580 |
Therapeutic
|
phenotype |
RGD |
Antithrombotic activity of kininogen is mediated by inhibitory effects of domain 3 during arterial injury in vivo.
|
17293494 |
2007 |
Thrombosis
|
0.580 |
Biomarker
|
phenotype |
LHGDN |
Molecular analysis of factor V Leiden, factor V Hong Kong, factor II G20210A, methylenetetrahydrofolate reductase C677T, and A1298C mutations related to Turkish thrombosis patients.
|
17911197 |
2007 |
Thrombosis
|
0.580 |
GeneticVariation
|
phenotype |
LHGDN |
The results indicate that FV Leiden prevalence is quite high and coexistence of FV Leiden with other hereditary causes of thrombosis such as prothrombin G20210A mutation and MTHFR enzyme defect is not rare in healthy population of Aegean region of Turkey.
|
17456626 |
2007 |
Thrombosis
|
0.580 |
GeneticVariation
|
phenotype |
LHGDN |
A 10-year-old boy with basilar artery thrombosis who was heterozygous for prothrombin G20210A mutation is described.
|
17621506 |
2007 |
Thrombosis
|
0.580 |
Biomarker
|
phenotype |
RGD |
Hematological and morphological investigation of thrombogenic mechanisms in the lungs of phenylhydrazine-treated rats.
|
22402172 |
2013 |